The transaction is expected to complete by early August, 2008. The financial details of the agreement were not disclosed.
Daiichi Sankyo said that the transaction may affect about 130 workers who are to be integrated into its sales force.
Thomson Financial has quoted Daiichi Sankyo, as saying: “The takeover of a working team that is experienced in cardiovascular diseases and successful is an excellent opportunity to satisfy demand for additional employees.”